Literature DB >> 32147798

CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.

Mélanie Lambert1, Caroline Leijonhufvud1, Filip Segerberg1, J Joseph Melenhorst2,3,4,5, Mattias Carlsten6.   

Abstract

Natural killer (NK) cells are cytotoxic lymphocytes of our immune system with the ability to identify and kill certain virally infected and tumor-transformed cells. During the past 15 years, it has become increasingly clear that NK cells are involved in tumor immune surveillance and that they can be utilized to treat cancer patients. However, their ability to induce durable responses in settings of adoptive cell therapy needs to be further improved. One possible approach is to genetically engineer NK cells to augment their cytotoxicity per se, but also their ability to persist in vivo and home to the tumor-bearing tissue. In recent years, investigators have explored the potential of viral transduction and mRNA electroporation to modify NK cells. Although these methods have generated promising data, they are associated with certain limitations. With the increasing advances in the CRISPR/Cas9 technology, investigators have now turned their attention toward using this technology with NK cells as an alternative method. In this book chapter, we introduce NK cells and provide an historical overview of techniques to genetically engineer lymphocytes. Further, we elucidate protocols for inducing double-strand breaks in NK cells via CRISPR/Cas9 together with readouts to address its efficacy and functional outcome. We also discuss the pros and cons of the described readouts. The overall aim of this book chapter is to help introduce the CRISPR/Cas9 technology to the broader audience of NK cell researchers.

Entities:  

Keywords:  CRISPR/Cas9; DNA sequencing; Digital droplet PCR; Flow cytometry; Gene editing; NK cells; RT-PCR

Mesh:

Year:  2020        PMID: 32147798     DOI: 10.1007/978-1-0716-0338-3_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  A robust platform for expansion and genome editing of primary human natural killer cells.

Authors:  Rih-Sheng Huang; Min-Chi Lai; Hsin-An Shih; Steven Lin
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

Review 2.  Engineered NK Cells Against Cancer and Their Potential Applications Beyond.

Authors:  Maria Karvouni; Marcos Vidal-Manrique; Andreas Lundqvist; Evren Alici
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

3.  A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes.

Authors:  Kanut Laoharawee; Matthew J Johnson; Walker S Lahr; Christopher J Sipe; Evan Kleinboehl; Joseph J Peterson; Cara-Lin Lonetree; Jason B Bell; Nicholas J Slipek; Andrew T Crane; Beau R Webber; Branden S Moriarity
Journal:  Int J Mol Sci       Date:  2022-08-28       Impact factor: 6.208

4.  An optimized platform for efficient siRNA delivery into human NK cells.

Authors:  Daniel Palacios; Pouria Momayyezi; Oisín Huhn; Eivind Heggernes Ask; Josefine Dunst; Karl-Johan Malmberg; Quirin Hammer
Journal:  Eur J Immunol       Date:  2022-04-22       Impact factor: 6.688

Review 5.  SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases.

Authors:  Mujahed I Mustafa; Abdelrafie M Makhawi
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

6.  Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications.

Authors:  Ida Friberger; Emma Jussing; Jinming Han; Jeroen A C M Goos; Jonathan Siikanen; Helen Kaipe; Mélanie Lambert; Robert A Harris; Erik Samén; Mattias Carlsten; Staffan Holmin; Thuy A Tran
Journal:  Mol Imaging Biol       Date:  2021-07-06       Impact factor: 3.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.